Sanofi Study Shows Extended Lovenox Regimen Reduces VTE Risk
Posted on: Monday, 9 July 2007, 12:21 CDT
Sanofi-Aventis says extending prophylaxis with its Clexane/Lovenox injection to five weeks is more effective than 10 days for reducing the risk of venous thromboembolism in patients, according to a new study.
Sanofi says that the study showed the benefit of extended prophylaxis in acutely ill medical patients with reduced mobility by demonstrating the superiority of a five week course of prophylaxis with Clexane/Lovenox (enoxaparin)compared to a 10 day regimen, with a statistically significant 44% reduction in venous thromboembolism (VTE) events (deep vein thrombosis and/or pulmonary embolism).
The benefit of thromboprophylaxis with enoxaparin (10 plus or minus 4 days) has already been demonstrated in this patient population and is considered as the standard regimen, says Sanofi. Nonetheless, clinical practice suggests that the risk of VTE may continue beyond 10 days, particularly in patients with reduced mobility.
The objective of the study was to assess the superiority of enoxaparin prophylaxis given for 28 plus or minus 4 days versus placebo, both following an initial treatment with enoxaparin for 10 plus or minus 4 days, to reduce VTE events rate. The primary efficacy endpoint was the incidence of asymptomatic deep-vein thrombosis (DVT), symptomatic DVT, symptomatic pulmonary embolism (PE), or fatal PE during the double-blind period.
The statistically significant 44% relative risk reduction in VTE events observed for extended-duration prophylaxis with enoxaparin vs. placebo for the primary endpoint was associated with a reduction in symptomatic VTE by 73% and asymptomatic proximal DVT by 34%. No statistically significant differences were observed for symptomatic pulmonary embolism (PE) or fatal PE.
"What the trial results showed is that patients do not leave their risk for VTE at the door when they leave the hospital," commented Victor Tapson, a lead investigator of the study.
Source: Datamonitor
Related Articles
- Study Suggests Dentists Can Identify Patients At Risk For Fatal Cardiovascular Event
- Study Suggests Dentists Can Identify Patients at Risk for Fatal Cardiovascular Event
- Isolagen, Inc. Reports Positive Top-Line Results From Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and Are Statistically Significant
- Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
- New Data Reveals That Enoxaparin Results in Significant Cost Savings Compared to Unfractionated Heparin (UFH) in Treatment of in-Hospital Patients at Risk for Venous Thromboembolism (VTE)
- Salix Announces Completion of First XIFAXAN(R) Travelers' Diarrhea Prevention Study; Study Results Highly Statistically Significant (P Less Than 0.0001)
- Actelion: Second Study With Bosentan (Tracleer) Demonstrating a Statistically Significant Reduction of New Digital Ulcers in Patients With Systemic Sclerosis
- Independent Clinical Review of Phase III Trial Shows Erbitux and Radiation Control Spread of Advanced Squamous Cell Cancer of the Head and Neck Better Than Radiation Alone; Primary and Secondary Study Endpoints Met With Statistical Significance
- Benefits Found in High Doses of Statins; Reducing Cholesterol in Heart Patients Lowers Risk of Heart Attacks, Strokes, 5-Year Study Shows
- Use of Investigational Agent Entecavir Demonstrated Statistically Significant Improvement in Liver Histology and Viral Suppression Compared to Lamivudine in Chronically Infected Hepatitis B E-Antigen (HBeAg) Positive Patients
 |
 |
User Comments (0)
RSS Feeds